SG11201708613SA - Novel crystal of uracil compound - Google Patents

Novel crystal of uracil compound

Info

Publication number
SG11201708613SA
SG11201708613SA SG11201708613SA SG11201708613SA SG11201708613SA SG 11201708613S A SG11201708613S A SG 11201708613SA SG 11201708613S A SG11201708613S A SG 11201708613SA SG 11201708613S A SG11201708613S A SG 11201708613SA SG 11201708613S A SG11201708613S A SG 11201708613SA
Authority
SG
Singapore
Prior art keywords
novel crystal
uracil compound
uracil
compound
crystal
Prior art date
Application number
SG11201708613SA
Inventor
Masayoshi Fukuoka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201708613SA publication Critical patent/SG11201708613SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201708613SA 2015-05-01 2016-04-28 Novel crystal of uracil compound SG11201708613SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015093862 2015-05-01
PCT/JP2016/063495 WO2016178416A1 (en) 2015-05-01 2016-04-28 Novel crystal of uracil compound

Publications (1)

Publication Number Publication Date
SG11201708613SA true SG11201708613SA (en) 2017-11-29

Family

ID=57217651

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708613SA SG11201708613SA (en) 2015-05-01 2016-04-28 Novel crystal of uracil compound

Country Status (15)

Country Link
US (1) US10259792B2 (en)
EP (1) EP3290406A4 (en)
JP (1) JP6479970B2 (en)
KR (2) KR20170137916A (en)
CN (1) CN107531646B (en)
AU (1) AU2016258388B2 (en)
BR (1) BR112017023649A2 (en)
CA (1) CA2984724C (en)
HK (1) HK1245770A1 (en)
MX (1) MX2017013969A (en)
MY (1) MY185785A (en)
PH (1) PH12017501948A1 (en)
RU (1) RU2686722C1 (en)
SG (1) SG11201708613SA (en)
WO (1) WO2016178416A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014107622A1 (en) 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
CN106061952B (en) 2014-01-03 2022-01-28 南加州大学 Heteroatom-containing deoxyuridine triphosphatase inhibitors
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
CN107922330A (en) 2015-07-08 2018-04-17 Cv6治疗(Ni)有限公司 The uracil deoxyriboside triphosphatase inhibitor of hydantoin-containing
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101384940B1 (en) * 2008-06-03 2014-04-11 다이호야쿠힌고교 가부시키가이샤 Novel uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof
JP2013032293A (en) * 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk 5-FLUOROURACIL COMPOUND HAVING HUMAN dUTPase-INHIBITING ACTIVITY OR SALT THEREOF
MX2012006183A (en) * 2009-11-30 2012-06-19 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator.

Also Published As

Publication number Publication date
PH12017501948A1 (en) 2018-03-19
JP6479970B2 (en) 2019-03-06
AU2016258388B2 (en) 2019-03-28
CN107531646B (en) 2020-11-03
JPWO2016178416A1 (en) 2017-10-26
CA2984724C (en) 2020-06-02
WO2016178416A1 (en) 2016-11-10
CN107531646A (en) 2018-01-02
RU2686722C1 (en) 2019-04-30
MY185785A (en) 2021-06-08
US10259792B2 (en) 2019-04-16
BR112017023649A2 (en) 2018-07-17
US20180134666A1 (en) 2018-05-17
EP3290406A4 (en) 2018-11-14
KR20200039846A (en) 2020-04-16
KR20170137916A (en) 2017-12-13
EP3290406A1 (en) 2018-03-07
HK1245770A1 (en) 2018-08-31
AU2016258388A1 (en) 2017-11-23
CA2984724A1 (en) 2016-11-10
MX2017013969A (en) 2018-02-21

Similar Documents

Publication Publication Date Title
HK1255921A1 (en) Pyrimidine compound
HK1245770A1 (en) Novel crystal of uracil compound
IL255817A (en) Synthesis of heterocyclic compounds
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
IL250022A0 (en) Novel substituted pyrimidine compounds
SI3380554T1 (en) Crystalline forms of per-chloro-gamma-cyclodextrines
HK1244274A1 (en) Crystalline forms of c21h22ci2n4o2
HK1250719A1 (en) Synthesis of desosamines
HUE066360T2 (en) Crystalline forms of eravacycline
IL253479A0 (en) Crystalline forms of efinaconazole
AP2016009506A0 (en) Pyrimidine compound
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL270961A (en) Crystalline form of n-butyldeoxygalactonojirimycin
SG11201704431VA (en) Novel salt of fused pyrimidine compound and crystal thereof
HUE050745T2 (en) Use of levelling compound
SI3424930T1 (en) Crystal of compound having jak-inhibiting activity
HK1247921A1 (en) New crystal of piperazine compound
PT3395819T (en) Crystal form of substituted aminopyran derivative